Date: December 12, 2019
Location: Renaissance Downtown Hotel, Washington, DC
Nixon Peabody partner Hannah Bornstein will be a co-presenter on the topic "Top Legal Threats and Trends Facing FDA-Regulated Companies," at FDLI's annual Enforcement, Litigation, and Compliance Conference in Washington, DC. This panel will focus on the top litigation and enforcement trends impacting companies. During this session, panelists will address enforcement trends and emerging areas of government focus that are important to consider when developing a compliance strategy and navigating the demanding regulatory regimes for FDA-regulated companies. Speakers will also address False Claims Act liability post-Escobar, where regulatory non-compliance can lead to False Claims Act liability, and DOJ’s recent Guidance on cooperation credit in False Claims Act matters.
The annual Enforcement, Litigation, and Compliance Conference brings together industry, regulators, attorneys, litigators, academics, and consultants to discuss trends and issues in enforcement and compliance, the latest developments in both civil and criminal litigation, and recent cases and settlements. This conference offers an opportunity to hear from and interact with top officials from FDA, DOJ, FTC, and other government agencies.
The conference includes a keynote address by FDA Chief Counsel Stacy Cline Amin on December 12.
To learn more or to register, visit the FDLI (Food and Drug Law Institute) Enforcement, Litigation, and Compliance Conference website.